Document is current
Any future updates will be listed below
-
Authors
Chen, Jian Jenny https://orcid.org/0009-0003-3598-8047
Vincent, Melanie Y.
Shepard, Dale
Peereboom, David
Mahalingam, Devalingam https://orcid.org/0000-0002-2979-9894
Battiste, James
Patel, Manish R.
Juric, Dejan
Wen, Patrick Y.
Bullock, Andrea https://orcid.org/0000-0001-7143-0225
Selfridge, Jennifer Eva
Pant, Shubham
Liu, Joyce
Li, Wendy
Fyfe, Susanne
Wang, Suming
Zota, Victor
Mahoney, James
Watnick, Randolph S.
Cieslewicz, Michael
Watnick, Jing https://orcid.org/0000-0003-0475-3299
- License Information
-
More Information
Article History
Received: 23 February 2023
Accepted: 3 May 2024
First Online: 21 May 2024
Competing interests
: Vigeo Therapeutics designed VT1021 and sponsored the trial in this article. R.S.W. is a co-founder of, and consultant for, Vigeo Therapeutics, which has licensed technology from Boston Children’s Hospital. V.Z. is a consultant for Vigeo Therapeutics. J.J.C., M.Y.V., W.L., S.F., S.W., J.M., M.C., and J.W. are employees of Vigeo Therapeutics. D.S., D.P., D.M., J.B., M.R.P., D.J., P.Y.W., A.B, J.E.S., S.P., and J.L. declare no competing interests.
